A T3587G germ-line mutation of the MDR1 gene encodes a nonfunctional P-glycoprotein

Molecular Cancer Therapeutics

Volumn 5, Issue 4, 2006, Pages 877-884

  Mutoh, Kazuyoshi ^a   Mitsuhashi, Junko ^a,b   Kimura, Yasuhisa ^d   Tsukahara, Satomi ^b   Ishikawa, Etsuko ^b   Sai, Kimie ^c   Ozawa, Shogo ^c   Sawada, Jun Ichi ^c   Ueda, Kazumitsu ^d   Katayama, Kazuhiro ^a   Sugimoto, Yoshikazu ^a,b  

^a KEIO UNIVERSITY   (Japan)

^b CANCER CHEMOTHERAPY CENTER   (Japan)

^c NATIONAL INSTITUTE OF HEALTH SCIENCES   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; COMPLEMENTARY DNA; DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; VINCRISTINE;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CANCER PATIENT; CELL POPULATION; CELL STRAIN 3T3; CELL SURFACE; CONTROLLED STUDY; ENZYME BINDING; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENE TRANSFER; GENETIC TRANSFECTION; GERM LINE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; KIDNEY CLEARANCE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; WESTERN BLOTTING;

3T3 CELLS; ADENOSINE TRIPHOSPHATE; AMINO ACID SEQUENCE; ANIMALS; ANTINEOPLASTIC AGENTS; BASE SEQUENCE; DNA PRIMERS; DRUG RESISTANCE, NEOPLASM; GENE TRANSFER TECHNIQUES; GERM-LINE MUTATION; HUMANS; JAPAN; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; P-GLYCOPROTEIN; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RETROVIRIDAE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33646545352     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-05-0240     Document Type: Article

References (42)

1. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V. Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 1985;316:817-9.
2. Chen CJ, Chin JE, Ueda K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986;47:381-9.
3. Shen DW, Fojo A, Chin JE, et al. Human multidrug-resistant cell lines: increased mdr1 expression can precede gene amplification. Science 1986;232:643-5.
4. Gottesman MM, Hrycyna CA, Schoenlein PV, Germamm UA, Pastan I. Genetic analysis of the multidrug transporter. Annu Rev Genet 1995;29:607-49.
5. Fojo AT, Ueda K, Slamon DJ, Poplack DG, Gottesman MM, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci U S A 1987;84:265-9.
6. Cordon-Cardo C, O'Brien JP, Casals D, et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 1989;86:695-8.
7. Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 1997;62:248-60.
8. van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P, van Tellingen O. Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice. J Natl Cancer Inst 1996;17:994-9.
9. Hori R, Okamura N, Aiba T, Tanigawara Y. Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney. J Pharmacol Exp Ther 1993;266:1620-5.
10. Merlin JL, Guerci A, Marchal S, et al. Comparative evaluation of S9788, verapamil, and cyclosporine A in K562 human leukemia cell lines and in P-glycoprotein-expressing samples from patients with hematologic malignancies. Blood 1994;84:262-9.
11. Mickisch GH, Kossig J, Keihauer G, Schlick E, Tschada RK, Alken PM. Effects of calcium antagonists in multidrug resistant primary human renal cell carcinomas. Cancer Res 1990;50:3670-4.
12. Schinkel AH, Wagenaar E, Mol CA, van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996;97:2517-24.
13. Schinkel AH, Mayer U, Wagenaar E, et al. Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci U S A 1997;94:4028-33.
14. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphism of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000;97:3473-8.
15. Kurata Y, Ieiri I, Kimura M, et al. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002;72:209-19.
16. + natural killer cells. Pharmacogenetics 2001;11:293-8.
17. Sai K, Kaniwa N, Itoda M, et al. Haplotype analysis of ABCB1/MDR1 blocks in a Japanese population reveals genotype-dependent renal clearance of irinotecan. Pharmacogenetics 2003;13:741-57.
18. Kiwaki K, Kanegae Y, Saito I, et al. Correction of ornithine transcarbamylase deficiency in adult spf(ash) mice and in OTC-deficient human hepatocytes with recombinant adenoviruses bearing the CAG promoter. Hum Gene Ther 1996;7:821-30.
19. Sugimoto Y, Tsukahara S, Sato S, et al. Drug-selected co-expression of P-glycoprotein and gp91 in vivo from an MDR1-bicistronic retrovirus vector Ha-MDR-IRES-gp91. J Gene Med 2003;5:366-76.
20. Kartner N, Evernden-Porelle D, Bradley G, Ling V. Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies. Nature 1985;316:820-3.
21. Takada Y, Yamada K, Taguchi Y, et al. Non-equivalent cooperation between the two nucleotide-binding folds of P-glycoprotein. Biochim Biophys Acta 1998;1373:131-6.
22. Payen LF, Gao M, Westlake CJ, Cole SPC, Deeley RG. Role of carboxylate residues adjacent to the conserved core Walker B motifs in the catalytic cycle of multidrug resistance protein 1 (ABCC1). J Biol Chem 2003;278:38537-47.
23. Ryu S, Kawage T, Nada S, Yamagichi A. Identification of basic residues involved in drug export function of human multidrug resistance-associated protein 2. J Biol Chem 2000;275:39617-24.
24. Sugimoto Y, Aksentijevich I, Gottesman MM, Pastan I. Efficient expression of drug-selectable genes in retroviral vectors under control of an internal ribosome entry site. Biotechnology 1994;12:694-8.
25. Zhang S, Sugimoto Y, Shoshani T, Pastan I, Gottesman MM. A pHaMDR-DHFR bicistronic expression system for mutation analysis of P-glycoprotein. Methods Enzymol 1998;292:474-80.
26. Sugimoto Y, Hrycyna C, Aksentijevich I, Pastan I, Gottesman MM. Co-expression of a multidrug resistahce gene (MDR1) and herpes simplex virus thymidine kinase gene as part of a bicistronic mRNA in a retrovirus vector allows selective killing of MDR1-transduced cells. Clin Cancer Res 1995;1:447-57.
27. Sugimoto Y, Sato S, Tsukahara S, et al. Coexpression of a multidrug resiatance gene (MDR1) and herpes simplex virus thymidine kinase gene in a bicistronic retroviral vector Ha-MDR-IRES-TK allows selective killing of MDR1-transduced human tumors transplanted in nude mice. Cancer Gene Ther 1997;4:51-8.
28. Sugimoto Y, Gottesman MM, Pastan I, Tsuruo T. Construction of MDR1 vectors for gene therapy. Methods Enzymol 1998;292:523-37.
29. Sugimoto Y, Aksentijevich I, Murray GJ, Brady RO, Pastan I, Gottesman MM. Retroviral coexpression of a multidrug resistance gene (MDR1) and human α-galactosidase A for gene therapy of Fabry disease. Hum Gene Ther 1995;6:905-15.
30. Suzuki M, Sugimoto Y, Tsukahara S, Okochi E, Gottesman MM, Tsuruo T. Retroviral co-expression of two different types of drug-resistant genes to protect normal cells from combination chemotherapy. Clin Cancer Res 1997;3:947-54.
31. 6-methylguanine-DNA methyltransferase using bicistronic vectors with human multidrug resistance gene 1. Mutat Res 1998;410:133-41.
32. Iwata M, Nunoi H, Matsuda I, Kanegasaki S, Tsuruo T, Sugimoto Y. Drug-selected complete restoration of superoxide generation in Epstein-Barr virus-transformed B cells from p47phox-deficient chronic granulomatous disease patients using a bicistronic retrovirus vector encoding a human multidrug resistance gene (MDR1) and the p47phox gene. Hum Genet 1998;103:419-23.
33. Sokolic RA, Sekhsaria S, Sugimoto Y, et al. A bicistronic retrovirus vector containing a picornavirus internal ribosome entry site allows for correction of X-linked CGD by selection for MDR1 expression. Blood 1996;87:42-50.
34. Imai Y, Nakane M, Kage K, et al. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol Cancer Ther 2002;1: 611-6.
35. Sugimoto Y, Tsukahara S, Ishikawa E, Mitsuhashi J. Breast cancer resistance protein: molecular target for anticancer drug resistance and pharmacokinetics/pharmacodynamics. Cancer Sci 2005;96:457-65.
36. Hashimoto K, Uchiumi T, Konno T, et al. Trafficking and functional defects by mutations of the ATP-binding domains in MRP2 in patients with Dubin-Johnson syndrome. Hepatology 2002;36:1236-45.
37. Keitel V, Kartenberk J, Nies AT, Spring H, Brom M, Keppler D. Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology 2000;32:1317-28.
38. Wada M, Toh S, Taniguchi K, et al. Mutations in the canalicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum Mol Genet 1998;7:203-7.
39. Gribar JJ, Ramachandra M, Hrycyna CA, Dey S, Ambudkar SV. Functional characterization of glycosylation-deficient human P-glycoprotein using a vaccinia virus expression system. J Membr Biol 2000;173:203-14.
40. Hrycyna CA, Ramachandra M, Germann UA, Cheng PW, Pastan L, Gottesman MM. Both ATP sites of human P-glycoprotein are essential but not symmetric. Biochemistry 1999;38:13887-99.
41. Urbatsch IL, Beaudet L, Carrier I, Gros P. Mutations in either nucleotide-binding site of P-glycoprotein (Mdr3) prevent vanadate trapping of nucleotide at both sites. Biochemistry 1998;37:4592-602.
42. Sparredoom A, Gelderblom H, Marsh S, et al. Diflomotecan pharmacokinetics in relation to ABCG2 421C> A genotype. Clin Pharmacol Ther 2004;76:38-44.